Brilacidin

<p>Brilacidin (formerly PMX-30063), an <a href="/facts/Investigational_new_drug/GTHo92ee">investigational new drug</a>, is a <a href="/facts/Polymer/eF32E50K">polymer</a>-based <a href="/facts/Antibiotic/sF1kIfxg">antibiotic</a> currently in human clinical trials, and represents a new class of antibiotics called host defense protein mimetics, or HDP-mimetics, which are non-<a href="/facts/Peptide/C4ltc7UG">peptide</a> synthetic small molecules modeled after <a href="/facts/Host_defense_peptides/sNRRb6sC">host defense peptides</a> (HDPs). HDPs, also called <a href="/facts/Antimicrobial_peptides/sNRRb6sC">antimicrobial peptides</a>, some of which are <a href="/facts/Defensins/BjSyPRDT">defensins</a>, are part of the <a href="/facts/Innate_immune_system/lz4BpSQI">innate immune</a> response and are common to most higher forms of life. As brilacidin is modeled after a defensin, it is also called a <a href="/facts/Defensin_mimetic/BjSyPRDT">defensin mimetic</a>.
</p><p>Brilacidin is an antibiotic that works by disrupting bacterial <a href="/facts/Cell_membrane/vAXSD0DT">cell membranes</a>, mimicking defensins that play a role in innate immunity. Several mimics of antimicrobial peptides, both peptides and non-peptides, have been studied, but none have overcome difficulties to reach the market.
</p>

Brilacidin open-in-new

Brilacidin